ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) develops and commercializes medical devices and services for minimally invasive neurosurgery, neurocritical care, and brain drug delivery. Its products include the ClearPoint navigation system, used to guide brain procedures such as electrode, biopsy needle, and laser catheter… From the company’s description.
Over the twelve months to Sep 30, 2026, ClearPoint Neuro, Inc. reported revenue of $45.49M, up 32.5% from a year earlier, and a net loss of $36.13M. Its operating margin was −70.6%, and operations used $32.17M in cash. In fiscal 2025, it reported revenue of $36.97M, up 17.8% from fiscal 2024, and a net loss of $25.54M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ClearPoint Neuro, Inc. does
In the company’s own words
ClearPoint Neuro, Inc. (Nasdaq: CLPT) develops and commercializes medical devices and services for minimally invasive neurosurgery, neurocritical care, and brain drug delivery. Its products include the ClearPoint navigation system, used to guide brain procedures such as electrode, biopsy needle, and laser catheter placement; the ClearPoint Prism laser therapy system; and the IRRAflow system, which combines intracranial irrigation, drainage, and pressure monitoring. The company also sells the SmartFlow Neuro cannula and provides preclinical research, clinical trial support, regulatory consultation, and other development services to pharmaceutical and biotechnology companies. Its business has two components: neurosurgical medical devices and biologics and drug delivery partnerships. Customers include hospitals and physicians, as well as pharmaceutical and biotechnology companies, academic institutions, and contract research organizations; it works with more than 60 such research and development partners. The 2025 acquisition of IRRAS expanded its portfolio into neurocritical care. ClearPoint Neuro reported approximately $[not stated] in revenue for fiscal 2025. Its website is www.clearpointneuro.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- SOLANA BEACH, CA
- Fiscal year end
- December
- CIK
- 1285550
- SIC
- 3841
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ClearPoint Neuro, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ClearPoint Neuro, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ClearPoint Neuro, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ClearPoint Neuro, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ClearPoint Neuro, Inc.'s last four quarterly filings that the numbers alone won't show?”